Repository logo
 

Kir6.1, a component of an ATP-sensitive potassium channel, regulates natural killer cell development.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

INTRODUCTION: Involved in immunity and reproduction, natural killer (NK) cells offer opportunities to develop new immunotherapies to treat infections and cancer or to alleviate pregnancy complications. Most current strategies use cytokines or antibodies to enhance NK-cell function, but none use ion channel modulators, which are widely used in clinical practice to treat hypertension, diabetes, epilepsy, and other conditions. Little is known about ion channels in NK cells. RESULTS: We show that Kcnj8, which codes for the Kir6.1 subunit of a certain type of ATP-sensitive potassium (KATP) channel, is highly expressed in murine splenic and uterine NK cells compared to other K+ channels previously identified in NK cells. Kcnj8 expression is highest in the most mature subset of splenic NK cells (CD27-/CD11b+) and in NKG2A+ or Ly49C/I+ educated uterine NK cells. Using patch clamping, we show that a subset of NK cells expresses a current sensitive to the Kir6.1 blocker PNU-37883A. Kcnj8 does not participate in NK cell degranulation in response to tumor cells in vitro or rejection of tumor cells in vivo, or IFN-γ release. Transcriptomics show that genes previously implicated in NK cell development are amongst those differentially expressed in CD27-/CD11b+ NK cells deficient for Kcnj8. Indeed, we found that mice with NK-cell specific Kcnj8 gene ablation have fewer CD27-/CD11b+ and KLRG-1+ NK cells in the bone barrow and spleen. DISCUSSION: These results show that the KATP subunit Kir6.1 has a key role in NK-cell development.

Description

Journal Title

Front Immunol

Conference Name

Journal ISSN

1664-3224
1664-3224

Volume Title

Publisher

Frontiers

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Wellcome Trust (200841/Z/16/Z)
Medical Research Council (MR/P001092/1)
This work was supported by NIH R01HL146514 and R01HL148609 (W.A.C), the Wellcome Trust 200841/Z/16/Z (F.C.) and R01 AI097302, R01 AI130143, and R01 DE027981 to S.F., R03 TR004157 and R03 TR004459 to W.A.C. and S.F. A.S. is funded by the Medical Research Council grant MR/P001092/1. The NYUMC Experimental Pathology [RRID:SCR_017928] is part of the Division of Advanced Research Technologies and has received funds by the following grants: NIH/NCI 5 P30CA16087 and S10 OD021747.